8 Gaps That Create Malpractice Exposure in a Ketamine Clinic
Three psychiatrists argued in MedPage Today this week that ketamine access is outrunning the standards meant to govern it. Their case is about patient safety. Read it as an operator and it is also a map of where claims come from. Here are the eight gaps that map points to.
Most of what follows costs nothing to fix. The premium is the part you negotiate. HealingMaps’ GPO, the first built for the ketamine industry, gets member clinics 15 to 20 percent off malpractice and liability premiums, 40 percent or more off medical supplies, discounted LegitScript certification, and 20 to 30 percent off HIPAA compliant payment processing. Joining is free with no obligation. See what your clinic qualifies for →
| Key Takeaway | Detail |
|---|---|
| The backdrop | The US ketamine market has passed $5 billion and is projected above $14 billion by 2035 |
| The warning | Anesthesiologists say access is expanding faster than patient safety standards |
| The asymmetry | Esketamine runs under a REMS program. Off-label ketamine has no equivalent |
| Where claims cluster | At-home use, thin monitoring, remote prescribing, and missing consent |
| The good news | Supervised in-person clinics show low rates of ketamine use disorder |
| The cheapest fix | Most of these gaps close with documentation rather than spending |
1. No Documented Substance Use Screen
This is the first thing a plaintiff looks for, and the easiest to get right.
American Psychiatric Association guidance flags a history of substance use disorder before prescribing. The esketamine label flags it too. Both call for careful assessment.
Careful assessment is not a box on an intake form. It is a risk-benefit decision, discussed with the patient and written into the record in the clinician’s own words.
One chart shows the question was asked, the answer weighed, the reasoning recorded. Another shows nothing. They are very different exhibits.
The same applies to the decision not to treat. A documented refusal, with the reasoning behind it, is a defense. An undocumented one looks like it never happened.
2. Consent That Lives in a Conversation
Lack of informed consent sits on the published list of ketamine malpractice exposures.
Off-label status belongs in that conversation. So do dissociation, blood pressure effects, driving restrictions, and the limits of what a course is expected to achieve.
Verbal consent happens in nearly every clinic. Documented consent, signed and specific to ketamine rather than to a generic procedure, happens in fewer.
Consent also has a shelf life. A form signed at intake does not cover a protocol change made eight months later.
3. Monitoring That Lapses Mid-Session
Inadequate monitoring of intravenous and intramuscular sessions is named directly as a source of claims.
The exposure is rarely the protocol on paper. It is the gap between the written protocol and what happens on a busy afternoon.
Who is in the room, what is recorded, at what interval, and who signs off before discharge. If those answers vary by staff member, the clinic has a standard in name only.
Vitals at fixed intervals, a named observer, and a discharge check with a signature. Three habits, no capital expense, and a contemporaneous record if anyone ever asks.
4. Prescribing Without an In-Person Evaluation
Prescribing through online platforms without an in-person evaluation is another listed exposure, and regulators have been active here.
We covered the FDA action against online ketamine sellers in July. The telehealth prescribing deadline remains the live operational question for any clinic with a remote intake.
The risk is not only regulatory. A remote evaluation can miss what an in-person one would have caught. That is the fact pattern a case gets built on.
5. No Defined Endpoint for the Course
The authors flag a shift from acute courses toward chronic ongoing use. They note that the effects of chronic use are largely unknown.
That shift creates a quiet liability. A patient on maintenance infusions for two years, with no documented reassessment, is hard to defend if anything goes wrong.
In the United Kingdom, people starting treatment for ketamine addiction rose more than eightfold in a decade. That is a different population and a different supply. It is also the context regulators read in.
Build a reassessment point into the protocol. Write down why treatment continues.
6. An At-Home Offering You Have Not Mapped
Unsupervised at-home use leads the published list of exposures, and lawsuits have already reached telehealth companies providing at-home ketamine.
Clinics that add a remote arm often inherit that exposure without pricing it. The supervision that makes the in-person model defensible does not travel with the prescription.
We looked at what the evidence does and does not support in our piece on an industry affiliated at-home injection study.
Three questions decide the exposure. Who assesses the patient, who holds the prescription, and who is responsible if a dose is taken unobserved. If those answers are unclear internally, they get settled externally.
7. A Protocol That Matches No Recognized Standard
There is no single enforced standard of care across ketamine clinics. That is precisely why adopting one voluntarily is protective.
The American Society of Anesthesiologists has called for stronger oversight of at-home delivery and more provider oversight inside clinics.
Esketamine shows what a governed version looks like. It is dispensed under a REMS program with defined monitoring. We described that in our look at its second FDA indication. Off-label ketamine has no equivalent.
Point to a published society guideline and show the clinic follows it. That is worth more than an internal document written from scratch.
8. A Policy You Have Not Read Since You Bought It
Most operators can name their carrier. Fewer can say what the policy actually covers. Off-label administration, a remote arm, a nurse working at the top of their license. Those are the questions.
Coverage written for a general psychiatry practice may not contemplate infusion monitoring at all.
Read the exclusions before a claim makes you read them. Then ask what the premium looks like with the first seven gaps closed, because carriers price documented protocols differently.
Data handling belongs in the same review. Exposure is not only clinical, as clinics learned when the FTC sued a telehealth company over tracking pixels.
The Part Worth Remembering
The same column that catalogs the risk also contains the best argument for supervised care.
One academic ketamine clinic has delivered more than 11,000 infusions and quadrupled its volume since 2018. In supervised, in-person settings like it, research and clinical experience point to a low prevalence of ketamine use disorder.
The model works. The exposure concentrates where supervision thins out.
Buyers already grade clinics on exactly these systems, as we found in our list of 9 things buyers check before an acquisition. Compliance work and enterprise value turn out to be the same work.
Patients comparing supervised options can start with our directory of verified ketamine clinics.
This article is for informational purposes and is not legal, medical or insurance advice. Consult your own counsel and carrier about your practice.
